Locally advanced pancreatic adenocarcinoma: Where are we and where are we going?

Journal of the Pancreas

Volumn 11, Issue 2, 2010, Pages 139-143

  Richter, Joshua ^a   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Gemcitabine; Neoadjuvant therapy; Pancreatic neoplasms

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CETUXIMAB; GEMCITABINE; OXALIPLATIN; S1; UNCLASSIFIED DRUG;

ACNE; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ALGORITHMS; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; DISEASE PROGRESSION; GASTROINTESTINAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS;

EID: 77749245779     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]
2. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2:865-7. [PMID 4186452]
3. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48:1705-10. [PMID 7284971]
4. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80:751-5. [PMID 2898536]
5. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3:373-8. [PMID 3973648]
6. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 20:326-31. [PMID 17235048]
7. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16. [PMID 15908661]
8. Crane CH, Varadhachary GR, Javle MM, Safran H, Krishnan S, Fleming JB, et al. Multi-institutional phase II trial of induction cetuximab, gemcitabine, and oxaliplatin, followed by radiotherapy with concurrent capecitabine, and cetuximab, for locally advanced pancreatic adenocarcinoma (LAPC). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 132.
9. Shinchi H, Takao S. Phase II study of oral fluoropyrimidine anticancer agent (S-1) with concurrent external-beam radiotherapy for locally advanced pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 196.
10. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakagawa N, et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg 2008; 195:757-62. [PMID 18367131]
11. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94:1575-9. [PMID 16721372]
12. Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse J, et al. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer 2007; 96:1650-5. [PMID 17533388]
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16. [PMID 10655437]
14. Moskovic DJ, Carlson PJ, Dakik HK, Qiao W, Javle MM, Fogelman DR. Factors predicting outcomes in patients with locally advanced pancreatic cancer (LAPC). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 218.
15. Raftery LL, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, et al. A phase I study of weekly oxaliplatin (Ox) and gemcitabine (Gem) during radiotherapy (RT) for unresectable pancreatic or biliary carcinoma. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 220.
16. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′- deoxycytidine. Int J Radiat Oncol Biol Phys 1996; 34:867-72. [PMID 8598364]
17. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002; 86:1551-4. [PMID 12085203]
18. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma V.1.2009. NCCN Clinical Practice Guidelines in Oncology.
19. Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010; 17:194-205. [PMID 19856029]
20. Nakachi K, Furuse J, Kinoshita T, Kawashima M, Ishii H, Ikeda M, et al. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2009 Dec 5. [PMID 19967537]
21. Watanabe F, Honda G, Kurata M, Tsuruta K, Tokashiki T, Funada N. A case report-neoadjuvant chemoradiotherapy with combination of S-1 and gemcitabine in a patient with locally advanced pancreatic cancer. Gan To Kagaku Ryoho 2009; 36:2430-2. [PMID 20037446]
22. de la Fouchardière C, Négrier S, Labrosse H, Martel Lafay I, Desseigne F, Méeus P, et al. Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010 Jan 28. [PMID 20116933]
23. Chadha MK, Litwin A, Levea C, Iyer R, Yang G, Javle M, Gibbs JF. Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. JOP. J Pancreas (Online) 2009; 10:535-8. [PMID 19734632]
24. Saif MW. Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007. JOP. J Pancreas (Online) 2007; 8:166-76. [PMID 17356239]